Article
Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
Expert opinion on pharmacotherapy - 1 May 2008
Cassier Philippe A, Dufresne Armelle, Arifi Samia, El Sayadi Hiba, Labidi Intidar, Ray-Coquard Isabelle, Tabone Séverine, Méeus Pierre, Ranchère Dominique, Sunyach Marie-Pierre, Decouvelaere Anne-Valérie, Alberti Laurent, Blay Jean-Yves
Abstract excerpt
BACKGROUND: The molecular hallmark of gastrointestinal stromal tumours (GISTs), the mutation of the KIT gene, was discovered 10 years ago. GISTs have since been recognized as separate pathological entities among sarcomas, and have become a model for targeted treatment of solid tumours. Imatinib mesilate, which was approved in 2002 for the treatment of patients with advanced GIST, has dramatically changed the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.